Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.
暂无分享,去创建一个
H. Kantarjian | J. Lipton | A. Hochhaus | M. Wetzler | F. Nicolini | P. Parikh | D. Raghunadharao | Dan Jones | A. Craig | E. Humphriss | J. Cortes-Franco | A. Benichou